Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Covington
Queensland Health
Mallinckrodt
Chubb
Colorcon
AstraZeneca
Moodys
Cipla

Generated: April 22, 2018

DrugPatentWatch Database Preview

VIRACEPT Drug Profile

« Back to Dashboard

When do Viracept patents expire, and when can generic versions of Viracept launch?

Viracept is a drug marketed by Agouron Pharms and is included in three NDAs.

The generic ingredient in VIRACEPT is nelfinavir mesylate. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the nelfinavir mesylate profile page.
Drug patent expirations by year for VIRACEPT
Pharmacology for VIRACEPT
Medical Subject Heading (MeSH) Categories for VIRACEPT
Synonyms for VIRACEPT
(3S, 4aS, 8aS)-2-[(2R, 3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzoylamino)-4-phenylthiobutyl]decahydroiso-quinoline-3-carboxylic acid t-butylamide methanesulfonate
(3S, 4aS, 8aS)-2-[(2R, 3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzoylamino)-4-phenylthiobutyl]decahydroisoquinoline-3-carboxylic acid t-butylamide methanesulfonate
(3S,4aS,8aS)-2-[(2R,3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzoylamino)-4-phenylthiobutyl]decahydroisoquinoline-3-carboxylic acid t-butylamide methanesulfonate
(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylsulfanyl)butyl]decahydroisoquinolinium methanesulfonate
(3S,4aS,8aS)-N-(1,1-Dimethylethyl)decahydro-2-[(2R,3R)-2- hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-3-isoquinolinecarboxamide methanesulfonate
(3S,4aS,8aS)-N-(1,1-Dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-3-isoquinolinecarboxamide
(3S,4aS,8aS)-N-tert-Butyl-2-((2R,3R)-3-(3,2-cresotamido)-2-hydroxy-4-(phenylthio)butyl)decahydro-3-isoquinolinecarboxamide monomethanesulfonate (salt)
(3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methyl-benzoyl)amino]-4-phenylsulfanyl-butyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide; methanesulfonic acid
(3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylsulfanyl)butyl]decahydroisoquinoline-3-carboxamide methanesulfonate
(3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]decahydroisoquinoline-3-carboxamide methanesulfonate (salt)
(3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide; methanesulfonic acid
159989-64-7 (Parent)
159989-65-8
3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-((2R,3R)-2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S,4aS,8aS)-, monomethanesulfonate (salt)
3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S-(2(2,S*,3S*),3-alpha,4a-beta,8a-beta))-, monomethanesulfonate (salt)
3-Isoquinolinecarboxamide,1-dimethylethyl)decahydro-2- [(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, methanesulfonate (3S,4aS,8aS)-
3S,4aS,8aS)-N-(1,1-Dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-3-isoquinolinecarboxamide methanesulfonate
989N658
98D603VP8V
AC-20033
AC1L20J3
AG 1343
AG-1343
AG-1346
AKOS015963185
Ambap159989-64-7
AN-31041
ARV-SR0121
AZT/3TC/NLFR combination
C08091
C32H45N3O4S.CH4O3S
C33H49N3O7S2
CAS-159989-65-8
CCG-100925
CHEBI:7497
CHEMBL1205
CPD000469186
CTK8E9065
D00899
DSSTox_CID_10777
DSSTox_GSID_33736
DSSTox_RID_79093
DTXSID2033736
HE315554
HMS2051N05
HMS2090L17
HMS2233M20
HMS3261P12
HSDB 7159
J-009662
KS-1089
LS-85416
LY-312857
MFCD00931436
MLS001055355
MLS001401378
MLS006010141
MolPort-005-938-420
N0986
NC00175
NCGC00090782-01
NCGC00090782-03
NCGC00090782-06
NCGC00258475-01
NCGC00261320-01
Nelfin
Nelfinavir mesilate
Nelfinavir mesilate (JAN)
Nelfinavir mesylate
Nelfinavir mesylate (USAN/INN)
Nelfinavir Mesylate [USAN]
Nelfinavir mesylate hydrate
Nelfinavir mesylate hydrate, >=98% (HPLC)
Nelfinavir Methanesulfonate
Nelfinavir methanesulfonate hydrate
Nelfinivir
NFV
NQHXCOAXSHGTIA-SKXNDZRYSA-N
NSC-722664
NSC722664
RT-014683
s4282
SAM001246655
SC-79735
SCHEMBL40942
SMR000469186
SYN3022
Tox21_111021
Tox21_111021_1
Tox21_200921
Tox21_500635
UNII-98D603VP8V
W-5226

US Patents and Regulatory Information for VIRACEPT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Agouron Pharms VIRACEPT nelfinavir mesylate POWDER;ORAL 020778-001 Mar 14, 1997 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Agouron Pharms VIRACEPT nelfinavir mesylate TABLET;ORAL 020779-001 Mar 14, 1997 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Agouron Pharms VIRACEPT nelfinavir mesylate TABLET;ORAL 021503-001 Apr 30, 2003 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for VIRACEPT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Agouron Pharms VIRACEPT nelfinavir mesylate POWDER;ORAL 020778-001 Mar 14, 1997 ➤ Sign Up ➤ Sign Up
Agouron Pharms VIRACEPT nelfinavir mesylate TABLET;ORAL 020779-001 Mar 14, 1997 ➤ Sign Up ➤ Sign Up
Agouron Pharms VIRACEPT nelfinavir mesylate TABLET;ORAL 020779-001 Mar 14, 1997 ➤ Sign Up ➤ Sign Up
Agouron Pharms VIRACEPT nelfinavir mesylate POWDER;ORAL 020778-001 Mar 14, 1997 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Chinese Patent Office
Julphar
US Department of Justice
Johnson and Johnson
Harvard Business School
Baxter
Chubb
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.